home / stock / prvb / prvb news

PRVB News and Press, Provention Bio Inc. From 04/02/19

Stock Information
Company Name: Provention Bio Inc.
Stock Symbol: PRVB
Market: NASDAQ
Website: proventionbio.com
Menu
PRVB PRVB Quote PRVB Short PRVB News PRVB Articles PRVB Message Board
Get PRVB Alerts

News, Short Squeeze, Breakout and More Instantly...
PRVB - Provention Bio Announces Key Additions to its Senior Management Team

OLDWICK, N.J. , April 2, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas Jacobstein , M.D., as Vice President of Clinica...
PRVB - Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors

OLDWICK, N.J. , March 28, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jeffrey Bluestone, PhD, to the Company's Board of Directors....

PRVB - Provention Bio's (PRVB) CEO Ashleigh Palmer on Q4 2018 Results - Earnings Call Transcript

Provention Bio, Inc. (PRVB) Q4 2018 Earnings Conference Call March 19, 2019 4:30 AM ET Company Participants Jason Rando – Investor Relations Ashleigh Palmer – Co-Founder and Chief Executive Officer Andrew Drechsler – Chief Financial Officer Francisco Leon &...

PRVB - Provention Bio beats by $0.04

Provention Bio (NASDAQ: PRVB ): Q4 GAAP EPS of -$0.15 beats by $0.04 . More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PRVB - Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

OLDWICK, N.J. , March 19, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, ...

PRVB - Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019

OLDWICK, N.J. , March 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and live audio webcast on Tuesday, March 19, 2019 ...

PRVB - Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference

OLDWICK, N.J. , Feb. 13, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today its Chief Executive Officer, Ash...
PRVB - Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

OLDWICK, N.J. , Jan. 28, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has received a Notice of Allo...

Previous 10 Next 10